These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 28603208)

  • 21. On the origin of Alzheimer's disease. Trials and tribulations of the amyloid hypothesis.
    Castello MA; Soriano S
    Ageing Res Rev; 2014 Jan; 13():10-2. PubMed ID: 24252390
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A century-old debate on protein aggregation and neurodegeneration enters the clinic.
    Lansbury PT; Lashuel HA
    Nature; 2006 Oct; 443(7113):774-9. PubMed ID: 17051203
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.
    Villemagne VL; Burnham S; Bourgeat P; Brown B; Ellis KA; Salvado O; Szoeke C; Macaulay SL; Martins R; Maruff P; Ames D; Rowe CC; Masters CL;
    Lancet Neurol; 2013 Apr; 12(4):357-67. PubMed ID: 23477989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exploring the Alzheimer amyloid-β peptide conformational ensemble: A review of molecular dynamics approaches.
    Tran L; Ha-Duong T
    Peptides; 2015 Jul; 69():86-91. PubMed ID: 25908410
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Amyloid beta plaque: a culprit for neurodegeneration.
    Gupta A; Goyal R
    Acta Neurol Belg; 2016 Dec; 116(4):445-450. PubMed ID: 27118573
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proteins in aggregates functionally impact multiple neurodegenerative disease models by forming proteasome-blocking complexes.
    Ayyadevara S; Balasubramaniam M; Gao Y; Yu LR; Alla R; Shmookler Reis R
    Aging Cell; 2015 Feb; 14(1):35-48. PubMed ID: 25510159
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemical modifications of amyloid-β(1-42) have a significant impact on the repertoire of brain amyloid-β(1-42) binding proteins.
    Medvedev AE; Buneeva OA; Kopylov AT; Mitkevich VA; Kozin SA; Zgoda VG; Makarov AA
    Biochimie; 2016; 128-129():55-8. PubMed ID: 27400251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The hippocampus in neurodegenerative disease.
    Moodley KK; Chan D
    Front Neurol Neurosci; 2014; 34():95-108. PubMed ID: 24777134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Transmission of pathogenic protein aggregates in Alzheimer's disease].
    Schwarzman AL; Sarantseva SV
    Mol Biol (Mosk); 2017; 51(3):418-422. PubMed ID: 28707657
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biomarker evidence for uncoupling of amyloid build-up and toxicity in Alzheimer's disease.
    Zetterberg H; Blennow K
    Alzheimers Dement; 2013 Jul; 9(4):459-62. PubMed ID: 23159047
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hyperspectral imaging signatures detect amyloidopathy in Alzheimer's mouse retina well before onset of cognitive decline.
    More SS; Vince R
    ACS Chem Neurosci; 2015 Feb; 6(2):306-15. PubMed ID: 25354367
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of intracellular amyloid beta in Alzheimer's disease.
    Li M; Chen L; Lee DH; Yu LC; Zhang Y
    Prog Neurobiol; 2007 Oct; 83(3):131-9. PubMed ID: 17889422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting oligomers in neurodegenerative disorders: lessons from α-synuclein, tau, and amyloid-β peptide.
    Gadad BS; Britton GB; Rao KS
    J Alzheimers Dis; 2011; 24 Suppl 2():223-32. PubMed ID: 21460436
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alzheimer's disease: a mathematical model for onset and progression.
    Bertsch M; Franchi B; Marcello N; Tesi MC; Tosin A
    Math Med Biol; 2017 Jun; 34(2):193-214. PubMed ID: 27079222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biomarkers of neurodegenerative disorders: how good are they?
    Rachakonda V; Pan TH; LE WD
    Cell Res; 2004 Oct; 14(5):347-58. PubMed ID: 15538967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stress proteins and glial functions: possible therapeutic targets for neurodegenerative disorders.
    Kitamura Y; Nomura Y
    Pharmacol Ther; 2003 Jan; 97(1):35-53. PubMed ID: 12493534
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intrinsically disordered proteins in various hypotheses on the pathogenesis of Alzheimer's and Parkinson's diseases.
    Coskuner O; Uversky VN
    Prog Mol Biol Transl Sci; 2019; 166():145-223. PubMed ID: 31521231
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Fragment-Based Method of Creating Small-Molecule Libraries to Target the Aggregation of Intrinsically Disordered Proteins.
    Joshi P; Chia S; Habchi J; Knowles TP; Dobson CM; Vendruscolo M
    ACS Comb Sci; 2016 Mar; 18(3):144-53. PubMed ID: 26923286
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advanced glycation end products and neurodegenerative diseases: mechanisms and perspective.
    Li J; Liu D; Sun L; Lu Y; Zhang Z
    J Neurol Sci; 2012 Jun; 317(1-2):1-5. PubMed ID: 22410257
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cdk5-Foxo3 axis: initially neuroprotective, eventually neurodegenerative in Alzheimer's disease models.
    Shi C; Viccaro K; Lee HG; Shah K
    J Cell Sci; 2016 May; 129(9):1815-1830. PubMed ID: 28157684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.